TherVacB – A THERAPEUTIC VACCINE TO CURE HEPATITIS B
European Commission and TherVacB join forces
The role of viral hepatitis as a public health threat has long been underestimated. Only very recently, the United Nations in their “2030 Agenda for Sustainable Development” called for international action to combat viral hepatitis and reduce the disease burden. The major killer is the hepatitis B virus (HBV) causing liver cirrhosis and liver cancer, and worldwide 880,000 humans die each year from the consequences of an HBV infection.
A prophylactic vaccine is available to prevent HBV infection, but more than 3% of the world’s population (about 260 million humans) are chronically infected and do not profit from that vaccine anymore. For those suffering from chronic hepatitis B, until today no curative treatment option exists.
The European Commission therefore selected the project TherVacB led by Helmholtz Zentrum München for a five-year funding within the Horizon 2020 program.
A consortium of leading virologists, immunologists and physicians specialized in treating viral hepatitis, will use a newly designed therapeutic vaccine, TherVacB, as an immunotherapy to cure HBV. TherVacB will be evaluated in a three-year clinical trial starting in 2021 conducted in Europe and in Africa. Integration of a partner site in Tanzania shall help building local capacities for diagnosing and treating hepatitis B and support an important goal of the consortium – to raise awareness for hepatitis B.
About TherVacB
For Patients
TherVacB Team
Partners
European countries
Project duration (months)
European Testing Week 15-22 May 2020
European Testing Week 2020 aims to increase testing efforts & promote awareness on the benefits of hepatitis/HIV testing! More details here.
World Hepatitis Day 28th July 2020!
Keep in mind! World Hepatitis Day (WHD) takes places every year on 28 July bringing the world together under a single theme to raise awareness of the global burden of viral hepatitis and to influence real change. Read more
The official kick-off meeting for TherVacB was held online!
Thanks to all TherVacB partners for taking time and for great discussions on how to cure hepatitis B patients!
Animation movie
Enjoy our animation movie to understand the mission and approach of the TherVacB project!
Did you miss today's #WHD2020 WHD webinar on how #COVID19 impacts on hepatitis elimination & what must be done to accelerate efforts to reach the 2030 goals? Thanks @Hep_Alliance for sharing the recorded discussion👏🏼
LIVE NOW
Our #WorldHepatitisDay webinar, "10 years to go: prospects of reaching the 2030 elimination targets in the context of #COVID19".
Tune in to this important discussion with leading experts from across the world below ⬇️ https://www.youtube.com/watch?v=h28IXSZS3PQ
In recognition of #WorldHepatitisDay we have put together a complimentary collection of related content selected by our Editors. This content is #free through Aug 4, 2020. Simply register your details to read the collection: https://hubs.ly/H0sxWyK0 #HepFreeFuture #nohep
Data from @ECDC_EU shows a high proportion of people with #HBV & #HCV are undiagnosed & those at high risk aren't being targeted for testing
This week was #WorldHepatitisDay but we must continue to close the testing gap for #hepatitis every day
➡️
Viral hepatitis: Europe needs to close the testing gap
Approximately four in five people living with hepatitis B and three out of four people with hepatitis C infection across the European Union and Europe...
bit.ly
#WorldHepatitisDay2020 is over, #LetsTalkHep today with the panelists @Hep_Alliance. Their free webinar just started about the ways in which civil society and the affected community can work to prevent mother to child transmission of #hepB. ⬇️👥🗓️
The role of community in the prevention of mother-to-child transmission
Join us as we explore the ways in which civil society and the affected community can work to prevent mother to child transmission of HBV
www.eventbrite.co.uk
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 848223.